<i>In vitro</i> susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
This study support the use of cefepime-enmetazobactam against ESBL/OXA-48-like co-producers. Cefepime-taniborbactam may be use against KPC and VIM producers and could represent a second-line option for NDM. Cefepime-zidebactam shows the most promising activity against MBLs, although already emerging resistance calls for caution.
Authors
- Inès Rezzoug (ORCID: https://orcid.org/0009-0006-9484-7932)
- Agnès B. Jousset (ORCID: https://orcid.org/0000-0002-8223-2213)
- Laurent Dortet (ORCID: https://orcid.org/0000-0001-6596-7384)
- Rémy A. Bonnin (ORCID: https://orcid.org/0000-0002-2307-3232)
- Cécile Emeraud (ORCID: https://orcid.org/0009-0006-3595-6434)
- Hippolyte De Swardt
- Marion Dutkiewicz
Institutions
- Inserm (FR)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- CEA Paris-Saclay (FR)
- CNR de la Résistance aux Antibiotiques (FR)
- Bicêtre Hospital (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1093/jac/dkaf440
- Citations
- 1
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.59